Loading news...
NEW YORK and NEW ORLEANS, Jan. 23, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Shareholders should contact the firm as there may be limited time to enforce your rights. Shareholders should contact the firm as there may be limited time to enforce your rights.
BALA CYNWYD, Pa. , Jan. 21, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith. com) or Marc Ackerman (mackerman@brodskysmith.
Shares of Ventyx Biosciences, Inc. (NASDAQ: VTYX - Get Free Report) have been given a consensus rating of "Reduce" by the nine analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and eight have given a hold rating to the company. The average 1-year target price among
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Cwm LLC decreased its stake in shares of Ventyx Biosciences, Inc. (NASDAQ: VTYX) by 66.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,279 shares of the company's stock after selling 37,866 shares during the quarter. Cwm LLC's holdings in
Ventyx Biosciences, Inc. (NASDAQ: VTYX - Get Free Report) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totaling 7,294,699 shares, a growth of 19.8% from the December 15th total of 6,089,007 shares. Approximately 12.5% of the shares of the stock are sold short. Based
NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
NEW YORK and NEW ORLEANS, Jan. 8, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
NEWTOWN, Pa., Jan. 8, 2026 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Ventyx Biosciences, Inc. ("Ventyx") (NASDAQ: VTYX), resulting from allegations of providing potentially misleading business information to the investing public.
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - January 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Eli Lilly and Company (NYSE: LLY) for $14.00 per share of common stock in an all-cash transaction (equal to an aggregate equity value of approximately $1.2 billion). The investigation concerns whether the Ventyx Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Ventyx Biosciences, Inc. (NASDAQ: VTYX) to Eli Lilly and Company for $14.00 per share is fair to Ventyx shareholders. Halper Sadeh encourages Ventyx shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Ventyx and it.
Eli Lilly (LLY) is in advanced discussions to acquire Ventyx Biosciences (VTYX), a move that could be valued at around $1 billion, according to people familiar
MILWAUKEE, Jan. 7, 2026 /PRNewswire/ -- Ademi LLP is investigating Ventyx (NASDAQ: VTYX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Eli Lilly. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
Eli Lilly confirmed its $1.2 billion plan late Wednesday to acquire Ventyx Biosciences. Ventyx stock ran up nearly 40% during regular trades.
Eli Lilly will buy Ventyx Biosciences in an all-cash deal worth $1.2 billion, the companies said on Wednesday, marking the Zepbound maker's latest push to expand beyond its blockbuster diabetes and weight-loss drugs.